Becton, Dickinson and Company

The forensic scores present a mixed but not alarming picture. The Beneish M-Score is -2.638, which is below -1.78 and therefore not in the elevated manipulation-risk zone. This is a screening measure, so it does not prove the figures are accurate, but it does not flag the earnings as elevated for manipulation. The Altman Z″-Score is 2.29, which sits in the grey zone between 1.10 and 2.60, meaning it is neither clearly safe nor clearly distressed; readers may want to weigh it against the debt load of $17.62 billion, which compares with equity of $25.39 billion at fiscal year-end 2025. The Piotroski F-Score is 6 of 8 computable signals, meaning six of the eight signals that could be computed were met. The Fog Index of 21.59 indicates the MD&A is very hard to read. Operating cash flow divided by net income was 2.04 in FY2025, so cash generation roughly doubled reported earnings, yet operating cash flow fell from $3.84 billion to $3.43 billion while net income moved from $1.71 billion to $1.68 billion. Long-term debt declined from $17.94 billion to $17.62 billion. Capital returns are sizable: the company paid $875 million in dividends and about $2.250 billion in repurchases during the first nine months of fiscal 2026, partly funded by a $4 billion cash distribution tied to the Transaction. Readers may want to look at Notes 2, 4 and 14 of the 10-Q, the segment recast in Note 8, and the risk-factor discussion of sole-sourced components and tariffs in the 10-K.

Catalyst.According to the 10-Q MD&A, the business is currently driven by volume growth after the February 9, 2026 spin-off of the Biosciences and Diagnostic Solutions business into a combination with Waters. For the quarter ended June 30, 2026, worldwide revenues of $4.983 billion rose 5.4%, with volume/other contributing 4.1 percentage points, pricing 0.3 points and foreign currency 1.0 point. Medical Essentials revenue grew 4.5% to $1,675 million, led by U.S. Vascular Access Management share gains. Management also says it continues to pursue tuck-in acquisitions, geographic expansion in emerging markets and new product programs.

Hidden risk.The 10-K annual figures were filed before the spin-off, while the 10-Q recasts prior periods as discontinued operations, so comparisons across these documents are not fully like-for-like. The MD&A Fog Index of 21.59 falls in the very hard to read band, which makes the narrative harder to check against the numbers. The filings also flag tariff exposure: management notes a remaining receivable for exemption claims whose collectability could be affected if mitigation strategies are rejected or eliminated. China volume-based procurement and lower vaccine demand are named as ongoing headwinds.